Mark Levis and Donald Small Pages 1183 - 1193 ( 11 )
Activating mutations of FLT3 (FMS-Like Tyrosine kinase-3) are the most common molecular abnormality in acute myeloid leukemia (AML). Their presence is associated with a worse prognosis, and the recognition of this has led to the development of several new small molecule FLT3 tyrosine kinase inhibitors. In this review, we summarize these developments and compare and contrast these novel agents both with regards to the assays used to characterize them as well as to their clinical potential.
flt3,aml,tyrosine kinase
, Johns Hopkins University School of Medicine Sidney Kimmel Comprehensive Cancer Center at JohnsHopkins Bunting-Blaustein Cancer Research Building, Room 251 1650 Orleans Street Baltimore, MD 21231-1000, USA.